TX SB 18: Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.
Texas SB 18 imposes new prohibitions on manufacturing and providing abortion-inducing drugs, with qui tam enforcement and protections against out-of-state counteractions.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Pharmaceutical manufacturers, API suppliers, and compounding facilities that produce or distribute abortion-inducing drugs in Texas or to Texas residents. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective immediately upon passage (exact date not specified in the excerpt).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New state-level prohibitions on the manufacture and provision of abortion-inducing drugs, including qui tam actions (private lawsuits) and jurisdictional protections against out-of-state judgments.
Who it affects
Pharmaceutical manufacturers, API suppliers, and compounding facilities that produce or distribute abortion-inducing drugs in Texas or to Texas residents.
What you must do
Review product portfolios to identify any abortion-inducing drugs and assess compliance with Texas SB 18; consult legal counsel to understand exposure and potential defenses.
Deadline
Effective immediately upon passage (exact date not specified in the excerpt).
Source: https://capitol.texas.gov/BillLookup/History.aspx?LegSess=892&Bill=SB18
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA Proposes New Registration and Listing Pathway for Distributed Manufacturing and Aligns Foreign Establishment Obligations With Current Law - arnoldporter.com
- FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing - manufacturingchemist.com
- FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars - Manufacturing Chemist
- FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products - foley.com
- US FDA proposes rule to simplify registration for some drug manufacturers - reuters.com